Marissa is an undergraduate at Harvard University studying in Molecular Biology and Computer Science. She's led independent biomedical research at top institutions and is interested in biotechnology startups, particularly ones taking innovative interdisciplinary approaches. She's the founder of Theraplexus, a biotechnology startup using artificial intelligence and cutting edge network science analytics for rapid, low cost drug discovery.

Shepherd Therapeutics transforms the rare cancer landscape

  Shepherd Therapeutics launched in 2016 with a mission to develop breakthrough treatments for rare cancers. Powered by artificial intelligence and machine learning, their drug development pipeline has already yielded seven promising drug assets in preclinical trials. With an innovative drug development pipeline and leadership with decades of experience in biotechnology, Shepherd Therapeutics was featured…